HC Wainwright Expects Lower Earnings for Nurix Therapeutics

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Stock analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Nurix Therapeutics in a research note issued to investors on Wednesday, January 29th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.72) per share for the quarter, down from their previous forecast of ($0.67). HC Wainwright has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Nurix Therapeutics' Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.00) EPS.

NRIX has been the topic of a number of other research reports. Stifel Nicolaus upped their target price on Nurix Therapeutics from $34.00 to $36.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Jefferies Financial Group started coverage on Nurix Therapeutics in a research report on Friday, October 11th. They issued a "buy" rating and a $41.00 price objective for the company. Stephens restated an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Morgan Stanley lifted their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a research report on Monday. Finally, UBS Group started coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They issued a "buy" rating and a $35.00 target price on the stock. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Nurix Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $31.12.

Nurix Therapeutics Stock Performance

Shares of NRIX stock traded down $0.35 during trading hours on Friday, reaching $18.60. The company had a trading volume of 535,739 shares, compared to its average volume of 659,174. Nurix Therapeutics has a 12-month low of $7.92 and a 12-month high of $29.56. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -6.44 and a beta of 2.14. The stock has a fifty day moving average of $19.99 and a 200-day moving average of $22.35.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of the company's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now owns 39,549 shares of the company's stock, valued at approximately $785,047.65. The trade was a 6.64 % decrease in their position. The disclosure for this sale can be found here. 9.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Nurix Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Nurix Therapeutics during the third quarter worth about $12,432,000. FMR LLC increased its position in Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company's stock worth $13,188,000 after buying an additional 511,256 shares during the period. Lord Abbett & CO. LLC purchased a new stake in Nurix Therapeutics in the third quarter valued at approximately $7,879,000. Patient Square Capital LP acquired a new stake in shares of Nurix Therapeutics in the third quarter valued at approximately $7,320,000. Finally, Wellington Management Group LLP grew its position in shares of Nurix Therapeutics by 8.8% during the third quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock worth $78,243,000 after acquiring an additional 280,240 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.